Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
17
Recruiting, industry sponsors, Gastroenterology and liver, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed158
17 trials
Showing 1 to 17, recently updated first.
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06318169 · 1,350 participants (planned) · Start Mar 13, 2024 · Primary completion Feb 28, 2029
Drug: Pegozafermin · For: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Sites: Birmingham, Alabama; Chandler, Arizona; Flagstaff, Arizona · 375 sites in all
- A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 WeeksPivotal-lookingRecruiting
Phathom Pharmaceuticals, Inc.Industry
NCT07752407 · 500 participants (planned) · Start Sep 25, 2026 · Primary completion Oct 20, 2027
Drug: Vonoprazan; Placebo · For: Symptomatic Non-erosive Gastroesophageal Reflux Disease
Sites: Phoenix, Arizona; Chula Vista, California; Lomita, California · 26 sites in all
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06419374 · 1,800 participants (planned) · Start May 24, 2024 · Primary completion Jun 30, 2028
Drug: Pegozafermin; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Sites: Birmingham, Alabama; Homewood, Alabama; Chandler, Arizona · 335 sites in all
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07854782 · 1,500 participants (planned) · Start Oct 28, 2026 · Primary completion Mar 3, 2029
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD
Sites: Miami, Florida; Marrero, Louisiana; Metairie, Louisiana · 5 sites in all
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPivotal-lookingRecruiting
Akero Therapeutics, IncIndustry
NCT06528314 · 2,150 participants (planned) · Start Oct 4, 2024 · Primary completion Feb 2030
Drug: Efruxifermin; Placebo · For: NASH - Nonalcoholic Steatohepatitis; MASH - Metabolic Dysfunction-Associated Steatohepatitis
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 359 sites in all
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisPivotal-lookingRecruiting
Akero Therapeutics, IncIndustry
NCT06215716 · 1,650 participants (planned) · Start Dec 1, 2023 · Primary completion Feb 2033
Drug: Efruxifermin; Placebo · For: NASH With Fibrosis; MASH With Fibrosis
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 361 sites in all
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT06051617 · 402 participants (planned) · Start Sep 7, 2023 · Primary completion Aug 2030
Drug: Seladelpar; Placebo · For: Primary Biliary Cholangitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Lancaster, California · 218 sites in all
- A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisPivotal-lookingRecruiting
IpsenIndustry
NCT06016842 · 276 participants (planned) · Start Aug 31, 2023 · Primary completion May 31, 2029
Drug: Elafibranor · For: Primary Biliary Cholangitis (PBC)
Sites: Tucson, Arizona; Little Rock, Arkansas; Coronado, California · 198 sites in all
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07112378 · 20 participants (planned) · Start Nov 10, 2025 · Primary completion Jun 19, 2028
Drug: dupilumab · For: Eosinophilic Esophagitis (EoE)
Sites: Phoenix, Arizona; San Francisco, California; Aurora, Colorado · 13 sites in all
- A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASHPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07581951 · 886 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 30, 2029
Drug: HSK31679; Placebo · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis; NASH (Non-Alcoholic Steatohepatitis)
Sites: Beijing, China
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASHPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07221188 · 1,250 participants (planned) · Start Dec 12, 2025 · Primary completion Mar 24, 2028
Drug: Efimosfermin Alfa; Placebo · For: Non-alcoholic Fatty Liver Disease
Sites: Arcadia, California; Covina, California; Los Angeles, California · 66 sites in all
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyPivotal-lookingRecruiting
Zydus Therapeutics Inc.Industry
NCT07424677 · 90 participants (planned) · Start Aug 11, 2026 · Primary completion Jul 2028
Drug: Saroglitazar Magnesium 1 mg; Placebo · For: Primary Biliary Cholangitis
Sites: Lakewood Rch, Florida
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesPivotal-lookingRecruiting
Zydus Therapeutics Inc.Industry
NCT07216235 · 386 participants (planned) · Start Mar 24, 2026 · Primary completion Nov 2032
Drug: Saroglitazar magnesium 1 mg; Placebo · For: Primary Biliary Cholangitis
Sites: Marietta, Georgia; Indianapolis, Indiana; Houston, Texas
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07221227 · 1,200 participants (planned) · Start Oct 24, 2025 · Primary completion Mar 29, 2028
Drug: Efimosfermin alfa; Efimosfermin alfa and 1 more · For: Non-alcoholic Fatty Liver Disease
Sites: Chandler, Arizona; Tucson, Arizona; Little Rock, Arkansas · 91 sites in all
- In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous DropPivotal-lookingRecruiting
Green Cross WellbeingIndustry
NCT06493799 · 226 participants (planned) · Start Jul 1, 2024 · Primary completion Mar 31, 2026
Drug: LAENNEC (Human Placenta Hydrolysate) IV; LAENNEC (Human Placenta Hydrolysate) SC · For: Chronic Liver Disease
Sites: Yongin-si, South Korea
- Saccharomyces Boulardii CNCM I-745 in Irritable Bowel SyndromePivotal-lookingRecruiting
BiocodexIndustry
NCT07168434 · 406 participants (planned) · Start Oct 22, 2025 · Primary completion Oct 11, 2026
Drug: Saccharomyces Boulardii 250 MG; Placebo 250 mg · For: IBS (Irritable Bowel Syndrome); IBS-D (Diarrhea-predominant); IBS, Mixed Symptoms
Sites: Braga, Portugal; Lisbon, Portugal; Barcelona, Spain · 10 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.